Shares shifted as Quantum Computing Inc. (QUBT) jumped +6.6% to $6.72 on October 16, two days after the company announced a collaboration with INmune Bio to apply quantum optimization and AI to Alzheimer's drug research. The deal is being marketed as QUBT's first-ever commercial customer in pharmaceuticals and biotech — a symbolic milestone for a company valued at roughly $1.55 billion despite trailing twelve-month revenue of just $9.8 million and persistent net losses.
A Foot in the Door for Pharma, but the Contract Is Small-Scale. The collaboration is labeled a "Stage 1 engagement,"
with the agreement providing options for additional work as INmune Bio advances its clinical programs. No financial terms were disclosed. The work combines INmune Bio's data from preclinical research through four clinical trials with QUBT's quantum optimization machine, aiming to find diseases driven by the same biology their investigational drug targets. In practical terms, QUBT is selling computing-as-a-service to help a biotech sift its data — useful, but not yet a large revenue stream.
Revenue Is Growing Fast from a Tiny Base — and Losses Are Growing, Too. Q2 2026 revenue jumped to $5.6 million from $61,000 a year earlier, and management reaffirmed 2026 core revenue guidance of $20–$25 million. Yet Q2 still produced a $1.2 million gross loss and a $23.0 million operating loss, while operating expenses more than doubled year-on-year. The pharma deal may help the narrative, but it won't close that gap anytime soon.
The Balance Sheet Buys Time, Not Proof. QUBT ended Q2 with $1.3 billion in cash and investments, total assets of $1.64 billion, and a contract backlog of approximately $42.5 million. That cash cushion — largely built from prior stock and warrant transactions — eliminates near-term survival risk. But the stock's viability ultimately depends on translating technological advances into sustainable revenue and eventual profitability.
The Market's Verdict Remains Mixed. According to six analysts, the average rating is "Buy" with a 12-month price target of $18.67 — implying roughly 173% upside. Yet QUBT has slid from $7.45 on October 8 to near its 52-week low of $6.18, a decline the INmune Bio announcement only partially reversed. One early-stage biotech deal — with no disclosed dollar value — signals commercial ambition, not commercial traction. Investors should watch whether "Stage 1" leads to a meaningful "Stage 2" before treating this as a turning point.